In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis

Nancy Olsen, Leigh F. Callahan, Theodore Pincus

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) patients whose unstimulated peripheral blood mononuclear cells produce high levels of IgM rheumatoid factor (IgM‐RF) in vitro have more severe disease activity. RA patients being treated with second‐line agents, including gold salts, penicillamine, or methotrexate, tend to be low producers or nonproducers of IgM‐RF in vitro. The possibility that low production or nonproduction of IgM‐RF in vitro may be explained by treatment with second‐line agents alone, irrespective of disease activity, was analyzed in 133 RA patients whose disease status was assessed by multiple laboratory and clinical measures. The results indicate that treatment with second‐line agents and in vitro IgM‐RF synthesis are independently associated with disease activity.

Original languageEnglish (US)
Pages (from-to)1090-1096
Number of pages7
JournalArthritis & Rheumatism
Volume31
Issue number9
DOIs
StatePublished - Jan 1 1988

Fingerprint

Rheumatoid Factor
Immunoglobulin M
Rheumatoid Arthritis
Pharmaceutical Preparations
Penicillamine
Methotrexate
Gold
Blood Cells
Salts
In Vitro Techniques
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

@article{634db386f4b34c9984264d9e6b7d60c1,
title = "In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) patients whose unstimulated peripheral blood mononuclear cells produce high levels of IgM rheumatoid factor (IgM‐RF) in vitro have more severe disease activity. RA patients being treated with second‐line agents, including gold salts, penicillamine, or methotrexate, tend to be low producers or nonproducers of IgM‐RF in vitro. The possibility that low production or nonproduction of IgM‐RF in vitro may be explained by treatment with second‐line agents alone, irrespective of disease activity, was analyzed in 133 RA patients whose disease status was assessed by multiple laboratory and clinical measures. The results indicate that treatment with second‐line agents and in vitro IgM‐RF synthesis are independently associated with disease activity.",
author = "Nancy Olsen and Callahan, {Leigh F.} and Theodore Pincus",
year = "1988",
month = "1",
day = "1",
doi = "10.1002/art.1780310902",
language = "English (US)",
volume = "31",
pages = "1090--1096",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis. / Olsen, Nancy; Callahan, Leigh F.; Pincus, Theodore.

In: Arthritis & Rheumatism, Vol. 31, No. 9, 01.01.1988, p. 1090-1096.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis

AU - Olsen, Nancy

AU - Callahan, Leigh F.

AU - Pincus, Theodore

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Rheumatoid arthritis (RA) patients whose unstimulated peripheral blood mononuclear cells produce high levels of IgM rheumatoid factor (IgM‐RF) in vitro have more severe disease activity. RA patients being treated with second‐line agents, including gold salts, penicillamine, or methotrexate, tend to be low producers or nonproducers of IgM‐RF in vitro. The possibility that low production or nonproduction of IgM‐RF in vitro may be explained by treatment with second‐line agents alone, irrespective of disease activity, was analyzed in 133 RA patients whose disease status was assessed by multiple laboratory and clinical measures. The results indicate that treatment with second‐line agents and in vitro IgM‐RF synthesis are independently associated with disease activity.

AB - Rheumatoid arthritis (RA) patients whose unstimulated peripheral blood mononuclear cells produce high levels of IgM rheumatoid factor (IgM‐RF) in vitro have more severe disease activity. RA patients being treated with second‐line agents, including gold salts, penicillamine, or methotrexate, tend to be low producers or nonproducers of IgM‐RF in vitro. The possibility that low production or nonproduction of IgM‐RF in vitro may be explained by treatment with second‐line agents alone, irrespective of disease activity, was analyzed in 133 RA patients whose disease status was assessed by multiple laboratory and clinical measures. The results indicate that treatment with second‐line agents and in vitro IgM‐RF synthesis are independently associated with disease activity.

UR - http://www.scopus.com/inward/record.url?scp=0023762245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023762245&partnerID=8YFLogxK

U2 - 10.1002/art.1780310902

DO - 10.1002/art.1780310902

M3 - Article

C2 - 3422013

AN - SCOPUS:0023762245

VL - 31

SP - 1090

EP - 1096

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -